Goldman Sachs Group, Inc. (The) reiterated their buy rating on shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) in a report issued on Friday, October 6th, MarketBeat Ratings reports. The firm currently has a $111.00 price objective on the biotechnology company’s stock.
Several other brokerages have also commented on ONCE. ValuEngine upgraded shares of Spark Therapeutics from a sell rating to a hold rating in a research report on Tuesday, June 20th. BidaskClub upgraded shares of Spark Therapeutics from a sell rating to a hold rating in a research report on Thursday, June 22nd. William Blair initiated coverage on shares of Spark Therapeutics in a research report on Wednesday, June 28th. They set an outperform rating on the stock. Jefferies Group LLC initiated coverage on shares of Spark Therapeutics in a research report on Monday, July 10th. They set a buy rating and a $85.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Spark Therapeutics from a hold rating to a sell rating in a research report on Wednesday, July 12th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $90.47.
Spark Therapeutics (ONCE) opened at 82.97 on Friday. The firm’s market cap is $2.59 billion. Spark Therapeutics has a 52 week low of $35.07 and a 52 week high of $91.75. The firm’s 50-day moving average is $85.85 and its 200-day moving average is $85.85.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) EPS for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business’s revenue was up 14.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.04) earnings per share. On average, equities analysts anticipate that Spark Therapeutics will post ($7.59) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://baseballnewssource.com/markets/goldman-sachs-group-inc-the-reaffirms-buy-rating-for-spark-therapeutics-inc-once/1700782.html.
In other Spark Therapeutics news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $84.63, for a total value of $84,630,000.00. Following the transaction, the director now directly owns 3,928,707 shares in the company, valued at approximately $332,486,473.41. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Katherine A. High sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total transaction of $430,800.00. Following the completion of the transaction, the insider now owns 215,000 shares in the company, valued at $18,524,400. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,333,195 shares of company stock worth $109,070,506. 7.30% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of ONCE. Ameritas Investment Partners Inc. increased its stake in shares of Spark Therapeutics by 23.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Spark Therapeutics during the 2nd quarter valued at about $143,000. BNP Paribas Arbitrage SA increased its stake in shares of Spark Therapeutics by 530.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after acquiring an additional 2,449 shares during the last quarter. Pacad Investment Ltd. increased its stake in shares of Spark Therapeutics by 75.0% during the 2nd quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Highbridge Capital Management LLC acquired a new position in shares of Spark Therapeutics during the 1st quarter valued at about $227,000. 77.84% of the stock is owned by institutional investors.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with our FREE daily email newsletter.